Meiqian Li

618 citations
12 papers · 407 indexed · 1 hit paper · h-index 9
Topics
Epigenetics and DNA Methylation (6 papers)Cancer-related gene regulation (5 papers)Bladder and Urothelial Cancer Treatments (4 papers)
Partner nations
ChinaUnited States

In The Last Decade

Meiqian Li

12 papers receiving 404 citations

Hit Papers

Cancer-Associated Fibroblast–Derived miR-146a-5p Generate...20232026202420252023255075

Peers

Meiqian Li
Comparison fields: 5 of 67
  • Molecular Biology 294
  • Cancer Research 126
  • Oncology 65
  • Surgery 58
  • Immunology 54
Replace Yunhong Zhan with:
Yunhong Zhan China
Chi‐Wei Chen Taiwan
Guoqiang Yan China
Xueyan Wu China
Jiacai Wu China
Young Kwon Hong South Korea
Alexander von Rücker Germany
Yonghui Li China
Samantha Williams United Kingdom
Meiqian Li relative to Yunhong Zhan China Yunhong Zhan's profile →
Citations per field
00.5×3.1×
Yunhong Zhan · 1×
Citations per year

Countries citing papers authored by Meiqian Li

Since Specialization
Citations

This map shows the geographic impact of Meiqian Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meiqian Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meiqian Li more than expected).

Fields of papers citing papers by Meiqian Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meiqian Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meiqian Li. The network helps show where Meiqian Li may publish in the future.

Co-authorship network of co-authors of Meiqian Li

This figure shows the co-authorship network connecting the top 25 collaborators of Meiqian Li. A scholar is included among the top collaborators of Meiqian Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meiqian Li. Meiqian Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 7
2
Cancer-Associated Fibroblast–Derived miR-146a-5p Generates a Niche That Promotes Bladder Cancer Stemness and Chemoresistancebreakdown →
96
3 6
4 17
5 39
6 10
7 23
8 1
9 22
10 49
11 91
12 46

About Meiqian Li

Meiqian Li is a scholar working on Urology, Hepatology and Statistics and Probability, having authored 12 papers that have together received 407 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (6 papers), Cancer-related gene regulation (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). The work is most often cited by research in Cancer Research (126 citations), Molecular Biology (294 citations) and Urology (19 citations). Meiqian Li has collaborated with scholars based in China and United States. Frequent co-authors include Ruimin Huang, Jun Yan, Hongqian Guo, Junlong Zhuang, Jingya Sun, Dong Yu, Zhen Zhu, Bing Shen, Dianzheng Zhang and Hongwen Zhu. Their work appears in journals such as Journal of Biological Chemistry, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026